Dr. Ahmet Özyiğit was born in 1981 in the Famagusta district of Cyprus. Ozgen and Dr. He is the youngest of Savaş Özyiğit's three children.

After completing his high school education at Türk Maarif College in 1998, he completed his undergraduate and graduate studies in economics in the American state of Kansas. Özyiğit, who later completed his doctorate education in the same field of science, published many articles in this field.

Özyiğit, who later became interested in medical science, studied medicine at the University of Nicosia Faculty of Medicine. In addition to this education, he received his master's degree in Clinical Embryology from the University of Leeds and postgraduate education in Endocrinology from the University of South Wales.

With an eclectic academic background, Dr. Özyiğit continues his clinical studies, especially on weight loss, metabolism and healthy aging. An active member of the American Academy of Anti-Aging Medicine, Dr. Özyiğit applies anti-aging, weight loss and brain function improving treatments to his patients.

TrueCheck: Preventing Cancer with Liquid Biopsy

TrueCheck: One Step Ahead Against Cancer with Liquid Biopsy

Time is our most valuable weapon in the fight against cancer. Early diagnosis is the most critical factor in altering the course of the disease. Cancer is often a silent traveler; it can progress through the body without symptoms for years. We can compare it to an iceberg: While nothing is visible on the surface, danger can grow deeper. The TrueCheck™ liquid biopsy test works like a radar, allowing us to detect this invisible iceberg underwater (Datar Cancer Genetics, 2023; Siegel et al., 2024).

What is TrueCheck™?

TrueCheck™ yalnızca bir kan örneği ile onlarca farklı kanser türü hakkında bilgi verebilen yenilikçi bir tarama testidir. Yaklaşık 70 farklı katı tümör tipini tarama kapasitesine sahiptir ve Avrupa’da görülen kanser vakalarının %80’inden fazlasını kapsar (Datar Cancer Genetics, 2023). Kadınlar için özel olarak geliştirilmiş FemmeSafe versiyonu ise meme, rahim, yumurtalık ve serviks kanserlerine odaklanır.

Unlike traditional screenings, this test isn't specific to any specific organ. While mammography only evaluates breast cancer and colonoscopy only evaluates the intestines, TrueCheck™ works like a detector that "scans" the entire body.

How Does It Work?

TrueCheck™ technology relies on detecting tumor cells and associated cell clusters released into the bloodstream. Normal cells are short-lived and die in a programmed manner after a certain period of time. Malignant cells, however, defy these biological rules, evade apoptosis, and survive (Shen et al., 2021).

In the laboratory, the blood sample is placed in an epigenetically activating medium (EAM). This medium accelerates the natural death of healthy cells, while tumor cells survive. This effectively activates a screening system, leaving only cancer-related cells (Datar Cancer Genetics, 2023). In the next step, these cells are labeled using multiple immunostaining techniques, and a crime scene examination is conducted under a microscope, gathering clues about the organ or tissue they originate from. This provides an answer not only to the question of whether cancer is present but also to the question of "where should it be sought?" (Lianidou & Pantel, 2020).

Clinical Performance

Yapılan klinik çalışmalarda TrueCheck™’in tümörleri yakalama duyarlılığı %88’e kadar, özgüllüğü ise %96–99 arasında bulunmuştur (Choudhury et al., 2022). Gerçek hayat verilerinde bile bu performans korunmuş, özellikle pankreas, akciğer ve yumurtalık gibi genellikle geç yakalanan kanserlerde oldukça umut verici sonuçlar elde edilmiştir (Patil et al., 2023). Bu sonuçlar, testin yanlış pozitif oranının düşük olduğunu ve gereksiz biyopsi veya görüntülemelere yol açma ihtimalinin oldukça sınırlı olduğunu gösterir.

Who is it recommended for?

TrueCheck™ can be used as part of a routine checkup program for healthy individuals over the age of 40. It's also logical to perform it at an earlier age for individuals with a family history of cancer, those with genetic risk factors such as BRCA1/2, or those who have been smoking for a long time (Ghavami et al., 2022). Risk is also higher for those with a history of obesity, type 2 diabetes, chronic inflammation, or viral infections (such as HBV and HPV). This test is particularly recommended for individuals without any symptoms, as this latent stage is often when cancer is most treatable (Siegel et al., 2024).

Advantages

TrueCheck™ is highly convenient for patients because it doesn't require a surgical biopsy. No additional procedures are required beyond a blood draw. Its ability to detect hidden cancer cells in different parts of the body with a single test is a key advantage that distinguishes it from other screening methods (Lianidou & Pantel, 2020).

Erken tanı konan bir kanserin tedavi başarısı dramatik biçimde yükselir. Örneğin, kolon kanserinde evre I’de 5 yıllık sağkalım %90’ın üzerindeyken, ileri evrelerde bu oran %15’in altına düşer (Siegel et al., 2024). TrueCheck™ bu farkı yaratacak fırsatı sunar.

Things to Consider

Her test gibi TrueCheck™ de mükemmel değildir. %100 duyarlılık sağlamaz, yani çok erken evrede bazı kanserler gözden kaçabilir. Bu nedenle mamografi, kolonoskopi gibi kanıta dayalı tarama yöntemlerinin yerine geçmez; onlarla birlikte kullanılmalıdır (NCCN, 2023). Ayrıca pozitif sonuç alan bir kişinin kaygısı artabilir; bu yüzden sonuçların mutlaka bir hekim tarafından değerlendirilmesi ve gerekirse ek görüntüleme veya biyopsi ile doğrulanması gerekir.

How Does the Process Work?

  1. Appointment and information: Your doctor will explain what the test is and its possible results.
  2. Blood collection: A total of 30 ml of blood is taken into 3 tubes.
  3. Laboratory phase: The sample is delivered to the center under special conditions, the cells are enriched and analyzed.
  4. Result: The report will be ready in approximately 10 business days.
  5. Interpretation: The physician evaluates the report together with other clinical findings and directs further examinations if necessary.

Clinical and Social Contribution

Early diagnosis reduces treatment costs for advanced cancers and improves quality of life (Mariotto et al., 2020). Encouraging screening habits in society reduces the burden of cancer not only at the individual level but also at the societal level. The TrueCheck™ liquid biopsy test offers a time-saving technology in the fight against cancer. When I recommend this test to my patients, my goal is to make the invisible visible and catch the disease at its earliest, most treatable stage. This is what a physician prioritizes: protecting their patients.

Source

  • Choudhury, R. et al. (2022). Clinical validation of circulating tumor-associated cell-based cancer screening. Cancer Research, 82(4): 678–689.
  • Datar Cancer Genetics. (2023). Trucheck™ – Early cancer detection test. Available at: https://www.datarpgx.de/en/trucheck-en/ (Accessed: 20 September 2025).
  • Ghavami, S. et al. (2022). Liquid biopsy in oncology: Opportunities and challenges. Molecular Cancer, 21(1): 86.
  • Lianidou, E. & Pantel, K. (2020). Liquid biopsies for cancer detection and monitoring. Clinical Chemistry, 66(1): 90–98.
  • Mariotto, A. et al. (2020). Economic impact of early cancer detection. JNCI, 112(9): 857–864.
  • NCCN (2023). NCCN Guidelines: Cancer Screening. Version 2.2023.
  • Patil, S. et al. (2023). Real-world performance of CTC-based cancer screening tests. Annals of Oncology, 34(5): 512–520.
  • Shen, Z. et al. (2021). CTC detection technologies and clinical applications. Nature Reviews Clinical Oncology, 18(9): 547–567.
  • Siegel, R.L. et al. (2024). Cancer statistics, 2024. CA: A Cancer Journal for Clinicians, 74(1): 5–33.
Home page Telephone WhatsApp E-mail Scroll Top